Target
Glutaminase kidney isoform, mitochondrial
Ligand
BDBM50548670
Substrate
n/a
Meas. Tech.
ChEMBL_2022795 (CHEMBL4676608)
IC50
16±n/a nM
Citation
 Soth, MJLe, KDi Francesco, MEHamilton, MMLiu, GBurke, JPCarroll, CLKovacs, JJBardenhagen, JPBristow, CACardozo, MCzako, Bde Stanchina, EFeng, NGarvey, JRGay, JPDo, MKGGreer, JHan, MHarris, AHerrera, ZHuang, SGiuliani, VJiang, YJohnson, SBJohnson, TAKang, ZLeonard, PGLiu, ZMcAfoos, TMiller, MMorlacchi, PMullinax, RAPalmer, WSPang, JRogers, NRudin, CMShepard, HESpencer, NDTheroff, JWu, QXu, AYau, JADraetta, GToniatti, CHeffernan, TPJones, P Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem 63:12957-12977 (2020) [PubMed]  Article 
Target
Name:
Glutaminase kidney isoform, mitochondrial
Synonyms:
GLS | GLS1 | GLSK_HUMAN | Glutaminase 1 | K-glutaminase | KIAA0838 | L-glutamine amidohydrolase
Type:
Protein
Mol. Mass.:
73471.89
Organism:
Homo sapiens (Human)
Description:
O94925
Residue:
669
Sequence:
MMRLRGSGMLRDLLLRSPAGVSATLRRAQPLVTLCRRPRGGGRPAAGPAAAARLHPWWGGGGWPAEPLARGLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEGKELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMDMLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKKQSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDLGTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQFLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSIEVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKLDPRREGGDQRVKSVINLLFAAYTGDVSALRRFALSAMDMEQRDYDSRTALHVAAAEGHVEVVKFLLEACKVNPFPKDRWNNTPMDEALHFGHHDVFKILQEYQVQYTPQGDSDNGKENQTVHKNLDGLL
  
Inhibitor
Name:
BDBM50548670
Synonyms:
CHEMBL4741924
Type:
Small organic molecule
Emp. Form.:
C24H27F3N8O3
Mol. Mass.:
532.5182
SMILES:
CNC(=O)c1cn(C[C@H](F)CCc2ccc(NC(=O)Cc3cc(OC4CC(F)(F)C4)cc(C)n3)nn2)nn1 |r|
Structure:
Search PDB for entries with ligand similarity: